Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2012. The report details a specific share repurchase transaction executed on March 15, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 550,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,438 pence per share; lowest price paid was 1,425.5 pence per share.
- Treasury Holdings (Settled): 512,997,927 shares (9.23% of total issued share capital).
- Treasury Holdings (Including Unsettled): 514,347,927 shares (10.20% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,045,073,198 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 550,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.20% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (512,997,927 settled) against the company's latest capitalization table.
- Confirm the total issued share capital excluding Treasury shares (5,045,073,198) for voting rights calculations.
- Review the remaining authorization for share buybacks under the mandate granted on May 5, 2011.
- Check subsequent filings for the settlement status of the 1,350,000 shares included in the "unsettled" count.